Role of Sodium Restriction and Diuretic Therapy for "Resistant" Hypertension in Chronic Kidney Disease

Seminars in Nephrology

Volumn 34, Issue 5, 2014, Pages 514-519

  Sinnakirouchenan, Ramapriya ^a   Kotchen, Theodore A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Chronic kidney disease; Diuretics; Resistant hypertension; Sodium

Indexed keywords

CHLORTALIDONE; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; ANTIHYPERTENSIVE AGENT; MINERALOCORTICOID ANTAGONIST; SALT INTAKE;

ALLERGIC REACTION; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DIURETIC ACTIVITY; DIURETIC THERAPY; DRUG EFFICACY; DRUG MECHANISM; FLUID BALANCE; GYNECOMASTIA; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERURICEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; INSULIN RESISTANCE; METABOLIC ALKALOSIS; NATRIURESIS; NEPHROLITHIASIS; NONHUMAN; OTOTOXICITY; RESISTANT HYPERTENSION; REVIEW; SODIUM BALANCE; SODIUM RESTRICTION; ADMINISTRATION AND DOSAGE; CHRONIC KIDNEY FAILURE; COMPLICATION; DRUG RESISTANCE; HYPERTENSION; SALT INTAKE;

ANTIHYPERTENSIVE AGENTS; DIURETICS; DRUG RESISTANCE; HUMANS; HYPERTENSION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RENAL INSUFFICIENCY, CHRONIC; SODIUM CHLORIDE, DIETARY;

EID: 84918494859     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2014.08.005     Document Type: Review

References (56)

1. Borst J.G., Borst-De Geus A. Hypertension explained by Starling's theory of circulatory homoeostasis. Lancet 1963, 1:677-682.
2. Bricker N.S., Fine L.G., Kaplan M., Epstein M., Bourgoignie J.J., Light A. "Magnification phenomenon" in chronic renal disease. N Engl J Med 1978, 299:1287-1293.
3. Kusaba T., Mori Y., Masami O., Hiroko N., Adachi T., Sugishita C., et al. Sodium restriction improves the gustatory threshold for salty taste in patients with chronic kidney disease. Kidney Int 2009, 76:638-643.
4. Slagman M.C., Waanders F., Hemmelder M.H., Woittiez A.J., Janssen W.M., Lambers Heerspink H.J., et al. HOlland NEphrology STudy Group. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 2011, 343:d4366.
5. Pimenta E., Gaddam K.K., Oparil S., Aban I., Husain S., Dell'Italia L.J., et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009, 54:475-481.
6. Koomans H.A., Roos J.C., Boer P., Geyskes G.G., Mees E.J. Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man. Hypertension 1982, 4:190-197.
7. Blythe W.B. Natural history of hypertension in renal parenchymal disease. Am J Kidney Dis 1985, 5:A50-A56.
8. Johnson R.J., Herrera-Acosta J., Schreiner G.F., Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002, 346:913-923.
9. De Nicola L., Minutolo R., Bellizzi V., Zoccali C., Cianciaruso B., Andreucci V.E., et al. investigators of the TArget Blood Pressure LEvels in Chronic Kidney Disease (TABLE in CKD) Study Group. Achievement of target blood pressure levels in chronic kidney disease: a salty question?. Am J Kidney Dis 2004, 43:782-795.
10. Weir M.R., Dengel D.R., Behrens M.T., Goldberg A.P. Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria. Hypertension 1995, 25:1339-1344.
11. Krikken J.A., Laverman G.D., Navis G. Benefits of dietary sodium restriction in the management of chronic kidney disease. Curr Opin Nephrol Hypertens 2009, 18:531-538.
12. Krikken J.A., Lely A.T., Bakker S.J., Navis G. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int 2007, 71:260-265.
13. Kotchen T.A., Cowley A.W., Frohlich E.D. Salt in health and disease--a delicate balance. N Engl J Med 2013, 368:1229-1237.
14. Dworkin L.D., Benstein J.A., Tolbert E., Feiner H.D. Salt restriction inhibits renal growth and stabilizes injury in rats with established renal disease. J Am Soc Nephrol 1996, 7:437-442.
15. Oudot C., Lajoix A.D., Jover B., Rugale C. Dietary sodium restriction prevents kidney damage in high fructose-fed rats. Kidney Int 2013, 83:674-683.
16. De Nicola L., Minutolo R., Gallo C., Zoccali C., Cianciaruso B., Conte M., et al. Management of hypertension in chronic kidney disease: the Italian multicentric study. J Nephrol 2005, 18:397-404.
17. McMahon E.J., Campbell K.L., Mudge D.W., Bauer J.D. Achieving salt restriction in chronic kidney disease. Int J Nephrol 2012, 2012:720429.
18. Agarwal R. Resistant hypertension and the neglected antihypertensive: sodium restriction. Nephrol Dial Transplant 2012, 27:4041-4045.
19. Kotchen T.A., Kotchen J.M., Boegehold M.A. Nutrition and hypertension prevention. Hypertension 1991, 18(Suppl):I115-120.
20. Institute of Medicine of the National Academies. Sodium intake in populations: assessment of evidence. May 14, 2013.
21. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Available at: . Accessed september 16, 2014. http://www.kidney.org/professionals/kdoqi/guidelines_bp/guide_12.htm.
22. Buerkert J., Martin D., Prasad J., Chambless S., Klahr S. Response of deep nephrons and the terminal collecting duct to a reduction in renal mass. Am J Physiol 1979, 236:F454-F464.
23. Ernst M.E., Moser M. Use of diuretics in patients with hypertension. N Engl J Med 2009, 361:2153-2164.
24. Eladari D., Chambrey R. Identification of a novel target of thiazide diuretics. J Nephrol 2011, 24:391-394.
25. Pickkers P., Hughes A.D., Russel F.G., Thien T., Smits P. Thiazide-induced vasodilation in humans is mediated by potassium channel activation. Hypertension 1998, 32:1071-1076.
26. Duarte J.D., Cooper-DeHoff R.M. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther 2010, 8:793-802.
27. Aleksandrow D., Wysznacka W., Gajewski J. Influence of chlorothiazide upon arterial responsiveness to nor-epinephrine in hypertensive subjects. N Engl J Med 1959, 261:1052-1055.
28. Freis E.D., Wanko A., Schnaper H.W., Frohlich E.D. Mechanism of the altered blood pressure responsiveness produced by chlorothiazide. J Clin Invest 1960, 39:1277-1281.
29. Zhu Z., Zhu S., Liu D., Cao T., Wang L., Tepel M. Thiazide-like diuretics attenuate agonist-induced vasoconstriction by calcium desensitization linked to Rho kinase. Hypertension 2005, 45:233-239.
30. Colas B., Slama M., Collin T., Safar M., Andrejak M. Mechanisms of methyclothiazide-induced inhibition of contractile responses in rat aorta. Eur J Pharmacol 2000, 408:63-67.
31. Knauf H., Mutschler E. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol 1995, 26:394-400.
32. Dussol B., Moussi-Frances J., Morange S., Somma-Delpero C., Mundler O., Berland Y. A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J Clin Hypertens (Greenwich) 2012, 14:32-37.
33. Roush G.C., Holford T.R., Guddati A.K. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012, 59:1110-1117.
34. Agarwal R., Sinha A.D. Thiazide diuretics in advanced chronic kidney disease. J Am Soc Hypertens 2012, 6:299-308.
35. Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension?. JAMA 1998, 279:1813-1816.
36. Gaddam K.K., Nishizaka M.K., Pratt-Ubunama M.N., Pimenta E., Aban I., Oparil S., et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008, 168:1159-1164.
37. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995, 9:145-149.
38. McKelvie R.S., Yusuf S., Pericak D., Avezum A., Burns R.J., Probstfield J., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999, 100:1056-1064.
39. Cicoira M., Zanolla L., Rossi A., Golia G., Franceschini L., Cabrini G., et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001, 37:1808-1812.
40. Jain G., Campbell R.C., Warnock D.G. Mineralocorticoid receptor blockers and chronic kidney disease. Clin J Am Soc Nephrol 2009, 4:1685-1691.
41. Bomback A.S., Klemmer P.J. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007, 3:486-492.
42. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
43. Sato A., Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 2003, 16:781-788.
44. Athyros V.G., Mikhailidis D.P., Kakafika A.I., Tziomalos K., Karagiannis A. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?. Expert Opin Pharmacother 2007, 8:529-535.
45. Pimenta E., Calhoun D.A. Resistant hypertension and aldosteronism. Curr Hypertens Rep 2007, 9:353-359.
46. Nishizaka M.K., Zaman M.A., Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925-930.
47. Václavík J., Sedlák R., Plachy M., Navrátil K., Plásek J., Jarkovsky J., et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011, 57:1069-1075.
48. Bomback A.S., Kshirsagar A.V., Amamoo M.A., Klemmer P.J. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008, 51:199-211.
49. Navaneethan S.D., Nigwekar S.U., Sehgal A.R., Strippoli G.F. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2009, 3:CD007004.
50. Guo C., Martinez-Vasquez D., Mendez G.P., Toniolo M.F., Yao T.M., Oestreicher E.M., et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 2006, 147:5363-5373.
51. Han S.Y., Kim C.H., Kim H.S., Jee Y.H., Song H.K., Lee M.H., et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006, 17:1362-1372.
52. Lee S.H., Yoo T.H., Nam B.Y., Kim D.K., Li J.J., Jung D.S., et al. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol Renal Physiol 2009, 297:F1381-F1390.
53. Toyonaga J., Tsuruya K., Ikeda H., Noguchi H., Yotsueda H., Fujisaki K., et al. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transplant 2011, 26:2475-2484.
54. Fujisawa G., Okada K., Muto S., Fujita N., Itabashi N., Kusano E., et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004, 66:1493-1502.
55. Yuan J., Jia R., Bao Y. Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats. J Renin Angiotensin Aldosterone Syst 2007, 8:118-126.
56. Palmer B.F. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004, 351:585-592.